Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?

  • Authors:
    • Leonardo Ferrari
    • Emilio Bajetta
    • Antonia Martinetti
    • Luigi Celio
    • Raffaella Longarini
    • Ignazia La Torre
    • Roberto Buzzoni
    • Luca Gattinoni
    • Ettore Seregni
    • Emilio Bombardieri
  • View Affiliations

  • Published online on: May 1, 2003     https://doi.org/10.3892/ijo.22.5.1081
  • Pages: 1081-1089
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Postmenopausal hormone-sensitive breast cancer is currently treated with either antioestrogens or aromatase inhibitors (AIs), due to the clinical efficacy and safety of these drugs. Today's challenge is the sequential use of AIs with different structure and no cross-resistance to improve the therapeutic outcome. The present study describes the biological action of the steroidal structure (SS)-AI exemestane (EXE), in patients progressing on aminoglutethimide (AG) or other non-steroidal structure (NSS)-AIs (letrozole or anastrozole). Thirteen patients were evaluated for serum insulin-like growth factor (IGF) components [total IGF-1, IGF-2 and IGF binding protein (IGFBP)-3], interleukin (IL)-6 system [IL-6 and soluble IL-6 receptor (sIL-6-R)] and bone metabolism markers [bone gla protein/osteocalcin (BGP), bone-specific isoform of alkaline phosphatase (BAP) and carboxy-telopeptide of type I procollagen (ICTP)]. IGF system components show a trend to increase both in patients progressing on AG and in patients progressing on other NSS-AIs. Such an increase depends on the wash-out lenght from the previous treatment and is strictly linked to the circulating oestrogen levels. Serum IL-6 and sIL-6-R are mainly related to the patients' clinical outcome. Bone formation (BGP and BAP) and bone resorption (ICTP) markers seem to be at equilibrium with oestrogen levels when starting EXE and do not appear to be uncoupled over treatment. The observed variations seem to be mainly linked to the circulating oestrogen levels rather than directly to the way of action of the AI employed.

Related Articles

Journal Cover

May 2003
Volume 22 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ferrari L, Bajetta E, Martinetti A, Celio L, Longarini R, La Torre I, Buzzoni R, Gattinoni L, Seregni E, Bombardieri E, Bombardieri E, et al: Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?. Int J Oncol 22: 1081-1089, 2003.
APA
Ferrari, L., Bajetta, E., Martinetti, A., Celio, L., Longarini, R., La Torre, I. ... Bombardieri, E. (2003). Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?. International Journal of Oncology, 22, 1081-1089. https://doi.org/10.3892/ijo.22.5.1081
MLA
Ferrari, L., Bajetta, E., Martinetti, A., Celio, L., Longarini, R., La Torre, I., Buzzoni, R., Gattinoni, L., Seregni, E., Bombardieri, E."Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?". International Journal of Oncology 22.5 (2003): 1081-1089.
Chicago
Ferrari, L., Bajetta, E., Martinetti, A., Celio, L., Longarini, R., La Torre, I., Buzzoni, R., Gattinoni, L., Seregni, E., Bombardieri, E."Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?". International Journal of Oncology 22, no. 5 (2003): 1081-1089. https://doi.org/10.3892/ijo.22.5.1081